India Molecular Diagnostics Market (By Product; By Test Location; By Technology: PCR, Sequencing; By Application: Oncology, Infectious Disease, Genetic Testing) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The India molecular diagnostics market was valued at USD 934.23 million in 2022 and it is predicted to surpass around USD 1,923.69 million by 2032 with a CAGR of 7.49% from 2023 to 2032.

Key Players

• The reagents segment dominated the India molecular diagnostics market with a revenue share of 65.34% in 2022.
• In 2022, the PCR technology segment held the largest revenue share of over 75.03%. 
• The infectious disease segment dominated the market with a revenue share of over 96.2% in 2022.

The central laboratories segment held the dominant revenue share of over 88.11% in 2022 and is anticipated to maintain its leading share in the forthcoming years.

The rising target disease burden, growing geriatric population, and introduction of technologically advanced products are the major factors driving the growth. Furthermore, the region reports an increase in the demand for POC facilities which is driving the industry’s growth. However, high prices of molecular diagnostic tests and poor reimbursement policies in the country are anticipated to restrain the market growth.

The geriatric population is rapidly increasing in India. As per the Government of India National Statistical Office, India’s geriatric population (aged 60 and above) is projected to rise by 41% over the next decade. It is expected to reach 194 million in 2031 from 138 million in 2021. Among the states, Kerala has the highest elderly population, with around 16.5% geriatric population, followed by Tamil Nadu, Himachal Pradesh, Bihar, Uttar Pradesh, and Assam.

Aging has become a substantial risk factor for numerous diseases, including obesity and diabetes, which, in turn, significantly increases the risk of infectious diseases. For example, the geriatric population is more likely to suffer from infectious diseases such as COVID-19 due to decreased immune function, multimorbidity, and physiological changes associated with aging. According to the WHO, until April 2020, around 95% of the deaths were reported among patients 60 years or above. Furthermore, more than 50% of deaths occurred in patients aged 80 years or older. Therefore, the growing aging population is driving the demand for diagnostics and factoring in the market’s growth.

Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high-impact rendering driver for India’s molecular diagnostics market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and QIAGEN are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors. The growing use of multiplex PCR technologies and real-time PCR equipment; e.g., EpiTect Methyl II PCR by QIAGEN for the detection of DNA methylation, is also likely to boost the market during the forecast period.

Key Players

• Abbott
• BD (Becton, Dickinson and Company)
• Biomérieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Hologic, Inc.
• Qiagen
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers
• Sysmex Corporation
• Diasorin S.P.A
• Mylab Discovery Solutions Private Limited
• Biogenix Inc. Pvt. Ltd
• Trivitron Healthcare
• POCT Services Private Limited

Market Segmentation

• By Product 
  
  • Instruments
  • Reagents
  • Others
• By Test Location
  
  • Point-Of-Care (POC)
  • Self-testing or OTC
  • Central Laboratories
• By Technology 
  
  • Polymerase chain reaction
    • PCR Market, By Type
      • Multiplex PCR
      • Other PCR
    • PCR Market, By Product
      • Instruments
      • Reagents
      • Others
  • In Situ Hybridization (ISH)
    • Instruments
    • Reagents
    • Others
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Instruments
    • Reagents
    • Others
  • Chips And Microarrays
    • Instruments
    • Reagents
    • Others
  • Mass Spectrometry
    • Instruments
    • Reagents
    • Others
  • Sequencing
    • Instruments
    • Reagents
    • Others
  • Transcription Mediated Amplification (TMA)
    • Instruments
    • Reagents
    • Others
  • Others
    • Instruments
    • Reagents
    • Others
• By Application 
  • Oncology
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Kidney Cancer
    • Liver Cancer
    • Blood Cancer
    • Lung Cancer
    • Other Cancers
  • Pharmacogenomics
  • Infectious Diseases
    • Methicillin-resistant Staphylococcus Aureus (MRSA)
    • Clostridium difficile
    • Vancomycin-Resistant Enterococci (VRE)
    • Carbapenem-resistant bacteria
    • Flu
    • Respiratory Syncytial Virus (RSV)
    • Candida
    • Tuberculosis (TB) and drug-resistant TBA
    • Meningitis
    • Gastrointestinal Panel Testing
    • Chlamydia
    • Gonorrhea
    • HIV
    • Hepatitis C
    • Hepatitis B
    • Other Infectious Diseases
  • Genetic Testing
    • Newborn Screening
    • Predictive And Presymptomatic Testing
    • Other Genetic Testing
  • Neurological Diseases
  • Cardiovascular diseases
  • Others